Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia

Executive Summary

Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.

You may also be interested in...



Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy

The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth. 

Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy

Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.

Keeping Track: Kite’s Tecartus Is Third CAR-T With US FDA Approval; Submissions Round-Up

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel